Financial reports
ARS
2023 FY
Annual report to shareholders
17 Apr 24
10-Q
2023 Q3
Quarterly report
6 Nov 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
10-Q
2023 Q1
Quarterly report
4 May 23
ARS
2022 FY
Annual report to shareholders
24 Apr 23
10-K
2022 FY
Annual report
3 Mar 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2021 Q1
Quarterly report
5 May 22
10-K
2021 FY
Annual report
9 Mar 22
Current reports
8-K
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes
14 Mar 24
8-K
March 2024 Corporate Presentation
6 Mar 24
8-K
Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference
5 Mar 24
8-K
Departure of Directors or Certain Officers
5 Mar 24
8-K
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
28 Feb 24
8-K
Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock
9 Jan 24
8-K
Other Events
4 Jan 24
8-K
January 2024 Corporate Presentation
3 Jan 24
8-K
Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition
11 Dec 23
8-K
Keros Therapeutics to Present at Upcoming Healthcare Conferences
7 Nov 23
Registration and prospectus
S-8
Registration of securities for employees
28 Feb 24
424B5
Prospectus supplement for primary offering
4 Jan 24
424B5
Prospectus supplement for primary offering
3 Jan 24
S-8
Registration of securities for employees
3 Mar 23
424B5
Prospectus supplement for primary offering
12 Dec 22
S-8
Registration of securities for employees
9 Mar 22
S-3ASR
Automatic shelf registration
3 May 21
S-8
Registration of securities for employees
15 Jan 21
424B4
Prospectus supplement with pricing info
13 Nov 20
POS EX
Additional exhibits for listing
13 Nov 20
Proxies
DEFA14A
Additional proxy soliciting materials
17 Apr 24
DEF 14A
Definitive proxy
17 Apr 24
DEFA14A
Additional proxy soliciting materials
24 Apr 23
DEF 14A
Definitive proxy
24 Apr 23
DEFA14A
Additional proxy soliciting materials
18 Apr 22
DEF 14A
Definitive proxy
18 Apr 22
DEFA14A
Additional proxy soliciting materials
19 Apr 21
DEF 14A
Definitive proxy
19 Apr 21
Other
EFFECT
Notice of effectiveness
13 Nov 20
CORRESP
Correspondence with SEC
10 Nov 20
CORRESP
Correspondence with SEC
10 Nov 20
UPLOAD
Letter from SEC
9 Nov 20
EFFECT
Notice of effectiveness
8 Apr 20
CERT
Certification of approval for exchange listing
6 Apr 20
CORRESP
Correspondence with SEC
3 Apr 20
CORRESP
Correspondence with SEC
3 Apr 20
CORRESP
Correspondence with SEC
30 Mar 20
CORRESP
Correspondence with SEC
16 Mar 20
Ownership
4
Jasbir Seehra
23 Feb 24
4
Jasbir Seehra
15 Feb 24
4
Keith Regnante
15 Feb 24
4
Christopher Rovaldi
15 Feb 24
4
Simon Peter Cooper
15 Feb 24
SC 13G/A
ALKEON CAPITAL MANAGEMENT LLC
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G/A
BlackRock Inc.
26 Jan 24
4
Keith Regnante
8 Jan 24
144
Notice of proposed sale of securities
4 Jan 24